Comparison of fasting bioavailability among 100-mg commercial, 100-mg generic, and 50-mg chewable generic sildenafil tablets in healthy male mexican volunteers: A single-dose, 3-period, crossover study

Clinical Therapeutics

Volumn 34, Issue 3, 2012, Pages 689-698

  Marcelín Jiménez, Gabriel ^a   Ángeles Moreno, Alionka P ^a   Contreras Zavala, Leticia ^b   García González, Alberto ^a   Ramírez San Juan, Eduardo ^b  

^a Global Bioanalytical Consulting   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

CAS no. 171599 83 0; Sildenafil chewable tablet tolerability; Sildenafil citrate bioavailability; Sildenafil pharmacokinetics; UPLC MS MS sildenafil quantification

Indexed keywords

SILDENAFIL; UNCLASSIFIED DRUG; VIMAX 100; VIMAX 50;

ADULT; ARTICLE; BIOEQUIVALENCE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; HEARTBURN; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; LINGUAL PARESTHESIA; MALE; MASS SPECTROMETRY; MEXICO; NORMAL HUMAN; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STOMACH PAIN; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VISUAL DISORDER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUGS, GENERIC; FASTING; HUMANS; MALE; MASTICATION; MEXICO; MIDDLE AGED; PIPERAZINES; PURINES; SULFONES; TABLETS; TANDEM MASS SPECTROMETRY; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84858593179     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.01.021     Document Type: Article

References (18)

1. Mexican Regulatory Web site (medicamentos de referencia) Referencias.pdf [in Spanish]. Acessed November 15, 2011. http://www.cofepris.gob.mx/AS/Paginas/RegistrosSanitarios/RegistroSanitarioMedicamentos.aspx.
2. Blumenthal D.K., Garrison J.C. Pharmacodynamics: molecular mechanisms of drug action. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2011, 41-72. McGraw Hill Medical, New York, NY. 12th ed. L.L. Brunton, B.A. Chabner, B.C. Knollman (Eds.).
3. Fraisse A., Wessel D.L. Acute pulmonary hypertension in infants and children: cGMP-related drugs. Pediatric Crit Care Med 2010, 11(Suppl 2):S37-S40.
4. Spillers J. Persistent pulmonary hypertension of the newborn: is sildenafil the new nitric?. A review of literature. Adv Neonatal Care 2010, 10:69-74.
5. Dhillon R. The management of neonatal pulmonary hypertension. Arch Dis Child Fetal Neonatal Ed 2011 Jan 30, [Epub ahead of print].
6. Nichols D.J., Muirhead G.J., Harness J.A. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002, 53(Suppl 1):5S-12S.
7. Al-Ghazawi M.A., Tutunji M.S., Aburuz S.M. The effect of pummel juice on pharmacokinetics of sildenafil in healthy adult male Jordanian volunteers. Eur J Clin Pharmacol 2010, 66:159-163.
8. Walker D.K., Ackland M.J., James G.C., et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog, and man. Xenobiotica 1999, 29:297-310.
9. Wang Y., Wang J., Cui Y., et al. Liquid chromatographic-tandem mass spectrometry method for the quantitation of sildenafil in human plasma. J Chromatogr A Analyt Technol Biomed Life Sci 2005, 828:118-121.
10. Vos R.M., Chahbouni A., Sinjewel A., et al. Quantitative analysis of sildenafil and demethylsildenafil in human serum by liquid chromatography-mass spectrometry with minimal sample pretreatment. J Chromatogr B Analyt Technol Biomed Life Sci 2008, 876:283-287.
11. Witjes B.C., Ahsman M.J., van der Najel B.C., et al. Simultaneous assay of sildenafil and demethylsildenafil in neonatal plasma by ultra-performance liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2010, 24:180-185.
12. NOM-177-SSA1-2008: Test and procedures to demonstrate interchangeability between pharmaceutical formulations [in Spanish] Mexican Health Ministry, Mexico, 2008, Accessed September 16, 2011. http://www.salud.gob.mx/unidades/cofepris/cis/tramites/regmed/pdf/NOM_%20177.pdf.
13. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence US Department of Health and Human Services, FDA-CDER, USA (2001), Accessed December 15, 2010. http://www.fda.gov/cder/guidance/3616fnl.pdf.
14. Yadav M., Shrivastav P.S. Incurred sample reanalysis (ISR): a decisive tool in bioanalytical research. Bioanalysis 2011, 3:1007-1024.
15. Flores M.F., Castañeda H.G., Granados S.V., et al. Increased bioavailability of sildenafil in Mexican men. JAMA 2000, 283:1825-1826.
16. Franco S.A., Almeida S., Filipe A., et al. Bioequivalence study of two tablet formulations of sildenafil. Arzneim-Forsch 2008, 58:122-125.
17. Kanjanawart S., Kongyingyoes B., Gaysomsiri D., et al. Bioequivalence and pharmacokinetic study of sildenafil in healthy Thai male volunteers. Srinagarind Med J 2008, 23:38-44.
18. Jarrar B.M. Histological alterations in the testicular tissue induced by sildenafil overdoses. Drug Metab Lett 2011, 5:99-103.